To see the other types of publications on this topic, follow the link: Facial hyperkinesis.

Journal articles on the topic 'Facial hyperkinesis'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Facial hyperkinesis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

May, Mark. "Management of Facial Hyperkinesis." Otology & Neurotology 23, Sup 1 (2002): S70. http://dx.doi.org/10.1097/00129492-200200001-00179.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Filipo, Roberto, Irma Spahiu, Edoardo Covelli, Maria Nicastri, and Gian Antonio Bertoli. "Botulinum toxin in the treatment of facial synkinesis and hyperkinesis." Laryngoscope 122, no. 2 (2012): 266–70. http://dx.doi.org/10.1002/lary.22404.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

de Maio, Maur??cio, and Ricardo Ferreira Bento. "Botulinum Toxin in Facial Palsy: An Effective Treatment for Contralateral Hyperkinesis." Plastic and Reconstructive Surgery 120, no. 4 (2007): 917–27. http://dx.doi.org/10.1097/01.prs.0000244311.72941.9a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, Jin. "Prevention and Treatment of Post-Paralytic Synkinesis: Critical Changes Following Severe Facial Palsy." Journal of Electrodiagnosis and Neuromuscular Diseases 26, no. 2 (2024): 19–24. http://dx.doi.org/10.18214/jend.2024.00038.

Full text
Abstract:
Facial synkinesis following severe facial palsy has been observed clinically across a wide range of patient groups, from infants to older adults, indicating that it is not limited to any specific demographic. In one of the largest studies on the natural progression of idiopathic peripheral facial nerve palsy, synkinesis was reported in approximately 16% to 55% of patients. The severity of facial synkinesis generally correlates with the severity of the initial facial palsy. Various types of nerve injuries have been categorized based on the extent of damage to the endoneurium, perineurium, and a
APA, Harvard, Vancouver, ISO, and other styles
5

Жучок, А. Н., та Т. Н. Чернуха. "Ботулинотерапия гемифациального спазма: обзор литературы". Неврология и нейрохирургия. Восточная Европа 15, № 1 (2025): 94–104. https://doi.org/10.34883/pi.2025.15.1.058.

Full text
Abstract:
Гемифациальный спазм (ГФС) относится к одному из наиболее распространенных краниофациальных двигательных расстройств, сопровождающихся вовлечением в гиперкинез мимической мускулатуры, иннервируемой волокнами лицевого нерва. Заболевание приводит к выраженной социальной дезадаптации пациентов, развитию тревожно-депрессивных расстройств и снижению качества жизни, что требует своевременного начала терапии с выбором оптимального лечебного подхода. Применение ботулинического токсина (БТ) при ГФС является одним из эффективных и безопасных методов лечения заболевания. Обладая мультимодальным действием
APA, Harvard, Vancouver, ISO, and other styles
6

Laskawi, R., and S. Rohrbach. "Selected Situations in the Treatment of Facial Hyperkinesis with Botulinum Toxin Type A." Otology & Neurotology 23, Sup 1 (2002): S90. http://dx.doi.org/10.1097/00129492-200200001-00234.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Artemenko, A. R., O. A. Shavlovskaya, and E. R. Mkhitaryan. "Specificity of using botulinic toxin type A for blepharospasm treatment." Clinician 13, no. 3-4 (2020): 43–52. http://dx.doi.org/10.17650/1818-8338-2019-13-3-4-43-52.

Full text
Abstract:
Blepharospasm (BS) is one of the diseases characterized exclusively by involuntary face movements (facial hyperkinesis). Typical clinical manifestations include squinting or increased blinking. Among frequent patients’ complains at the disease onset are unpleasant irritations, a foreign body sensation, itching, dry eyes, and frequent blinking. Dynamism is a typical BS feature: 1) it increases during emotional stress, in stressful situations, during fatigue, eye strain (reading), in bright light; 2) disappears while sleeping; 3) decreases after waking up; 4) «corrective gestures», such as touch
APA, Harvard, Vancouver, ISO, and other styles
8

Neville, Catriona, Vanessa Venables, Margaret Aslet, Charles Nduka, and Ruben Kannan. "An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire." Journal of Plastic, Reconstructive & Aesthetic Surgery 70, no. 11 (2017): 1624–28. http://dx.doi.org/10.1016/j.bjps.2017.05.048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nitta, Naoki, Naotaka Usui, Akihiko Kondo, et al. "Semiology of hyperkinetic seizures of frontal versus temporal lobe origin." Epileptic Disorders 21, no. 2 (2019): 154–65. http://dx.doi.org/10.1684/epd.2019.1047.

Full text
Abstract:
ABSTRACT Aims . Hyperkinetic seizures are usually associated with frontal lobe epilepsy. However, some patients have hyperkinetic seizures of temporal lobe origin. The semiological differences in hyperkinetic seizures between frontal and temporal lobe epilepsy have not been well studied. Here, we retrospectively assessed ictal semiology in order to distinguish between hyperkinetic seizures of frontal lobe origin and those of temporal lobe origin. Methods . We retrospectively reviewed data on patients who had undergone surgery for hyperkinetic seizures of temporal or frontal lobe origin and ach
APA, Harvard, Vancouver, ISO, and other styles
10

Judelson, Y. B., and N. Р. Gribova. "Exteroceptive suppression in facial hyperkineses and dystonias." Neurology Bulletin XXIX, no. 1-2 (1997): 88–90. http://dx.doi.org/10.17816/nb79930.

Full text
Abstract:
On the basis of study of results of exteroceptive suppression parameters in 140 patients with different variants of facial hyperkineses the state of reflex inhibitory neuronal chains was defined more precisely. Received data may be used in process selection and monitoring of therapy and promote to understanding of facial musculature dyskinesia forming mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
11

Dobie, R. A., and U. Fisch. "Primary and Revision Surgery (Selective Neurectomy) for Facial Hyperkinesia." Archives of Otolaryngology - Head and Neck Surgery 112, no. 2 (1986): 154–63. http://dx.doi.org/10.1001/archotol.1986.03780020034009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kim, Eugene J., Jay B. Reeck, and Corey S. Maas. "A Validated Rating Scale for Hyperkinetic Facial Lines." Archives of Facial Plastic Surgery 6, no. 4 (2004): 253–56. http://dx.doi.org/10.1001/archfaci.6.4.253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Kula, Asl, Zeliha ne, and Vildan zel. "Effects of delay in botulinum toxin treatment on patients with hyperkinetic facial disorders." Annals of Medical Research 30, no. 12 (2023): 1. http://dx.doi.org/10.5455/annalsmedres.2023.09.262.

Full text
Abstract:
Objective: Hyperkinetic facial disorders include Benign Essential Blepharospasm (BEB) and Hemifacial Spasm (HFS), which involve involuntary facial muscle contractions. Botulinum toxin (BTX) is essential for relieving symptoms. The Coronavirus-19 (COVID-19) pandemic-related restrictions have led to delays in receiving BTX treatment. This study aims to assess the impact of BTX treatment delays of affected patients. Materials and Methods: This study retrospectively examined the data of 84 patients (68 HFS and 16 BEB) whose BTX appointments were delayed due to COVID-19 restrictions. Patient status
APA, Harvard, Vancouver, ISO, and other styles
14

Goodman, Greg. "Botulinum toxin for the correction of hyperkinetic facial lines." Australasian Journal of Dermatology 39, no. 3 (1998): 158–63. http://dx.doi.org/10.1111/j.1440-0960.1998.tb01272.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Varanda, Sara, Sofia Rocha, Margarida Rodrigues, Álvaro Machado, and Gisela Carneiro. "Role of the “other Babinski sign” in hyperkinetic facial disorders." Journal of the Neurological Sciences 378 (July 2017): 36–37. http://dx.doi.org/10.1016/j.jns.2017.04.036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Ramirez, Alexander L., Jay Reeck, and Corey S. Maas. "PRELIMINARY EXPERIENCE WITH BOTULINUM TOXIN TYPE B IN HYPERKINETIC FACIAL LINES." Plastic and Reconstructive Surgery 109, no. 6 (2002): 2154–55. http://dx.doi.org/10.1097/00006534-200205000-00061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Lee, Yoon Se, Joong Ho Ahn, Hong Ju Park, et al. "Dual Coaptation of Facial Nerve Using Masseteric Branch of Trigeminal Nerve for Iatrogenic Facial Palsy: Preliminary Reports." Annals of Otology, Rhinology & Laryngology 129, no. 5 (2019): 505–11. http://dx.doi.org/10.1177/0003489419893722.

Full text
Abstract:
Objectives: Immediate facial nerve substitution or graft technique has been used for the repair of facial nerve defects occurring as a result of tumour dissection. However, some patients report unsatisfactory outcomes, such as difficulty in maintaining resting or smiling symmetry, due to persistent flaccid facial palsy. Here we evaluated the functional outcomes of transferring the masseteric branch of the trigeminal nerve to the facial nerve adjunct to facial nerve graft. Methods: We reviewed the medical records of seven patients who underwent facial reanimation surgery between 2014 and 2016.
APA, Harvard, Vancouver, ISO, and other styles
18

Ramirez, Alexander L., Jay Reeck, and Corey S. Maas. "Botulinum Toxin Type B (MyoBloc) in the Management of Hyperkinetic Facial Lines." Otolaryngology–Head and Neck Surgery 126, no. 5 (2002): 459–67. http://dx.doi.org/10.1067/mhn.2002.124706.

Full text
Abstract:
OBJECTIVE: Our goal was to evaluate the safety and efficacy of botulinum toxin type B (BTX-B) in the management of hyperfunctional facial lines. STUDY DESIGN AND SETTING: Twenty-four patients from an academic faculty practice were treated with 400 to 800 units BTX-B in the corrugator, orbicularis oculi, or frontalis. Patients were evaluated with the Wrinkle Improvement Score (WIS) and Rated Numeric Kinetic Line Scale (RNKLS) and questioned about side effects and pain. Evaluations were made at 1, 2, 4, 8, and 12 weeks. RESULTS: Onset of effect was within 72 hours. WIS and RNKLS for all sites we
APA, Harvard, Vancouver, ISO, and other styles
19

Manganelli, Fiore, Raffaele Dubbioso, Marcello Esposito, et al. "A case of congenital cataracts, facial dysmorphisms, neuropathy, and hyperkinetic movement disorder." Movement Disorders 28, no. 4 (2013): 559–60. http://dx.doi.org/10.1002/mds.25308.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Rohrich, Rod J., and Jeffrey E. Janis. "Botox for the Treatment of Dynamic and Hyperkinetic Facial Lines and Furrows: Adjunctive Use in Facial Aesthetic Surgery." Plastic and Reconstructive Surgery 112, Supplement (2003): 53S—54S. http://dx.doi.org/10.1097/01.prs.0000082193.79684.91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Fagien, Steven. "Botox for the Treatment of Dynamic and Hyperkinetic Facial Lines and Furrows: Adjunctive Use in Facial Aesthetic Surgery." Plastic and Reconstructive Surgery 112, Supplement (2003): 40S—52S. http://dx.doi.org/10.1097/00006534-200310001-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Fagien, Steven. "Botox for the Treatment of Dynamic and Hyperkinetic Facial Lines and Furrows: Adjunctive Use in Facial Aesthetic Surgery." Plastic and Reconstructive Surgery 103, no. 2 (1999): 701–13. http://dx.doi.org/10.1097/00006534-199902000-00055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Müller, Jörg, Gregor K. Wenning, Jörg Wissel, and Werner Poewe. "Intrafamilial heterogeneity of facial hyperkinesias: Chance association of tics, cranial dystonia, and Huntington's disease?" Movement Disorders 16, no. 2 (2001): 370–72. http://dx.doi.org/10.1002/mds.1058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Ahn, Ki-Young, Mee-Yeong Park, Dae-Hwan Park, and Dong-Gil Han. "Botulinum Toxin A for the Treatment of Facial Hyperkinetic Wrinkle Lines in Koreans." Plastic and Reconstructive Surgery 112, Supplement (2003): 141S—147S. http://dx.doi.org/10.1097/00006534-200310001-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Ahn, Ki-Young, Mee-Yeong Park, Dae-Hwan Park, and Dong-Gil Han. "Botulinum Toxin A for the Treatment of Facial Hyperkinetic Wrinkle Lines in Koreans." Plastic & Reconstructive Surgery 105, no. 2 (2000): 778–84. http://dx.doi.org/10.1097/00006534-200002000-00050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Svyrydova, N. K., Y. O. Trufanov, A. V. Artemenko, A. M. Rakhnianska, and S. O. Schurevskyy. "The Tourette’s syndrome: clinical case." East European Journal of Neurology, no. 1(7) (March 20, 2016): 12–17. http://dx.doi.org/10.33444/2411-5797.2016.1(7).12-17.

Full text
Abstract:
Tourette’s Syndrome (TS) — is the complex of symptoms of affection of the central nervous system, characterized by paroxysmal (rarely permanent) tic muscle twitching of face, neck, upper and lower extremities, hyperkinesia of respiratory muscles and facial muscles with involuntary exclamations of impulsive individual sounds or words [1]. The disease has an autosomal recessive inheritance and with disease onset in children aged 2 to 14 years, and boys get sick 2-3 times more likely than girls. Pathology does not affect life expectancy and mental development [2]. 
 This article describes a
APA, Harvard, Vancouver, ISO, and other styles
27

Kim, Eugene J., Alexander L. Ramirez, Jay B. Reeck, and Corey S. Maas. "The Role of Botulinum Toxin Type B (Myobloc) in the Treatment of Hyperkinetic Facial Lines." Plastic and Reconstructive Surgery 112, Supplement (2003): 88S—93S. http://dx.doi.org/10.1097/01.prs.0000082197.88799.84.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Rohrich, Rod J., and Jeffrey E. Janis. "The Role of Botulinum Toxin Type B (Myobloc) in the Treatment of Hyperkinetic Facial Lines." Plastic and Reconstructive Surgery 112, Supplement (2003): 94S—95S. http://dx.doi.org/10.1097/01.prs.0000082198.10443.9c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Fagien, Steven. "The Role of Botulinum Toxin Type B (Myobloc) in the Treatment of Hyperkinetic Facial Lines." Plastic and Reconstructive Surgery 112, Supplement (2003): 96S—97S. http://dx.doi.org/10.1097/01.prs.0000082199.42730.2a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Keen, M., A. Blitzer, J. Aviv, et al. "Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study." Ophthalmic Plastic & Reconstructive Surgery 12, no. 1 (1996): 69–70. http://dx.doi.org/10.1097/00002341-199603000-00019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Keen, Monte, Andrew Blitzer, Jonathan Aviv, et al. "Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study." Plastic and Reconstructive Surgery 94, no. 1 (1994): 94–99. http://dx.doi.org/10.1097/00006534-199407000-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Petrov, Konstantin B., Natalya A. Ivonina, and Tatiana V. Mitichkina. "Motoric Automatisms of the Maxillofacial Region: a Lecture." Bulletin of Rehabilitation Medicine 21, no. 6 (2022): 145–55. http://dx.doi.org/10.38025/2078-1962-2022-21-6-145-155.

Full text
Abstract:
INTRODUCTION. Effective kinesitherapy of peripheral and central paralysis of the mimic, masticatory, lingual and pharyngeal muscles requires in-depth study of the features of the cooperative work of these muscles in the norm and in pathology. AIM. To acquaint rehabilitation specialists with motor automatisms of the brachiofacial area and show the principles of their practical use. MATERIAL AND METHODS. We studied more than 70 literature sources on involuntary activity of the maxillofacial region and adjacent regions muscles as well as we summarized our own experience in rehabilitation of patie
APA, Harvard, Vancouver, ISO, and other styles
33

Bowler, Patrick J. "Dermal and epidermal remodeling using botulinum toxin type A for facial, nonreducible, hyperkinetic lines: two case studies." Journal of Cosmetic Dermatology 7, no. 3 (2008): 241–44. http://dx.doi.org/10.1111/j.1473-2165.2008.00399.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Vyskub, M. "Import substitution of botulinum toxin preparations in cosmetologist's practice: experience of using Miotox® preparation." Vrach 34, no. 7 (2023): 21–25. http://dx.doi.org/10.29296/25877305-2023-07-04.

Full text
Abstract:
Botulinum therapy is the most popular medical cosmetology procedure in the world. At the moment 9 preparations of botulinum toxin type A-hemagglutinin complex are officially registered in Russia, only Miotox® is available in liquid form as a solution for intramuscular injection. The study of pharmacoepidemiology of botulinum toxin preparations in cosmetology practice and studies to evaluate their efficacy and safety will allow to specify their clinical and pharmacological advantages. Objective. To study the pharmacoepidemiology, safety, tolerability and efficacy of Miotox® in cosmetology pract
APA, Harvard, Vancouver, ISO, and other styles
35

Danti, Federica Rachele, Serena Galosi, Marta Romani, et al. "GNAO1 encephalopathy." Neurology Genetics 3, no. 2 (2017): e143. http://dx.doi.org/10.1212/nxg.0000000000000143.

Full text
Abstract:
Objective:To describe better the motor phenotype, molecular genetic features, and clinical course of GNAO1-related disease.Methods:We reviewed clinical information, video recordings, and neuroimaging of a newly identified cohort of 7 patients with de novo missense and splice site GNAO1 mutations, detected by next-generation sequencing techniques.Results:Patients first presented in early childhood (median age of presentation 10 months, range 0–48 months), with a wide range of clinical symptoms ranging from severe motor and cognitive impairment with marked choreoathetosis, self-injurious behavio
APA, Harvard, Vancouver, ISO, and other styles
36

Spiga Real, Daniel Sundfeld, Mateus Fagundes Goes, and Bianca Sato Fernandes. "Phenomenon of "Sismonasty" in the Use of Botulinum Toxin for Treatment of Hyperkinetic Facial Wrinkles: A Case Report." ARC Journal of Surgery 10, no. 1 (2024): 35–38. http://dx.doi.org/10.20431/2455-572x.1001005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Mastrangelo, Mario, Chiara Commone, Carlo Greco, and Vincenzo Leuzzi. "TSC1 as a Novel Gene for Sleep-Related Hypermotor Epilepsy: A Child with a Mild Phenotype of Tuberous Sclerosis." Neuropediatrics 52, no. 02 (2021): 146–49. http://dx.doi.org/10.1055/s-0041-1722881.

Full text
Abstract:
AbstractSleep-related hypermotor epilepsy (SHE) is a rare syndrome that presents with hyperkinetic asymmetric tonic/dystonic seizures with vegetative signs, vocalization, and emotional facial expression, mainly during light non-rapid eye movement sleep stages. The role of various genes (CHRNA4, CHRNB2, CHRNA2, KCNT1, DEPDC5, NPRL2, NPRL3, and PRIMA1) has previously been reported, though genetic etiology is assessed in less than 10% of cases. We report the case of a 5-year-old female carrying the TSC1 variant c.843del p.(Ser282Glnfs*36) who presented with a mild phenotype of tuberous sclerosis,
APA, Harvard, Vancouver, ISO, and other styles
38

McMillan, HJ, A. Telegrafi, A. Singleton, et al. "B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45, s2 (2018): S12. http://dx.doi.org/10.1017/cjn.2018.90.

Full text
Abstract:
Background:ATP8A2 mutations have only recently been associated with human disease. We present the clinical features from the largest cohort of patients with this disorder reported to date. Methods: An observational study of 9 unreported and 2 previously reported patients with biallelic ATP8A2 mutations was carried out at multiple centres. Results: The mean age of the cohort was 9.4 years old (range: 2.5-28 yrs). All patients demonstrated developmental delay, severe hypotonia and movement disorders: chorea/choreoathetosis (100%), dystonia (27%) or facial dyskinesia (18%). Hypotonia was apparent
APA, Harvard, Vancouver, ISO, and other styles
39

Romeo, Domenico M., Alessandro Specchia, Alfonso Fasano, et al. "Treatment of Dystonia Using Trihexyphenidyl in Costello Syndrome." Brain Sciences 10, no. 7 (2020): 450. http://dx.doi.org/10.3390/brainsci10070450.

Full text
Abstract:
Costello syndrome (CS), a rare syndrome with multisystemic involvement inherited as a dominant trait, is characterized by developmental delay, coarse facial appearance, cardiac defects including hypertrophic cardiomyopathy, skin abnormalities, brain complications, and a predisposition to certain malignancies. The musculoskeletal system is particularly affected in CS, with peculiar orthopedic anomalies that impact posture and gait. Dystonia has been recently documented to contribute to abnormal postures and musculoskeletal anomalies characterizing CS, suggesting the possible use of pharmacologi
APA, Harvard, Vancouver, ISO, and other styles
40

Lerman-Sagie, Tally, Ana Westenberger, Hilla Ben-Pazi, et al. "Multiple Causes of Pediatric Early Onset Chorea—Clinical and Genetic Approach." Neuropediatrics 49, no. 04 (2018): 246–55. http://dx.doi.org/10.1055/s-0038-1645884.

Full text
Abstract:
Objective This article elucidates a clinical and genetic approach to pediatric early-onset chorea in patients with normal neuroimaging. Methods We retrospectively studied patients with onset hyperkinetic movement disorders. Only children with onset of chorea in the first 3 years of life were included, those with an abnormal magnetic resonance imaging (MRI) or electroencephalogram (EEG) were excluded.We studied the movement disorder phenotype by clinical examination and by interpretation of videos and compared our data to the literature. Results Four patients, aged 2 to 13 years, were diagnosed
APA, Harvard, Vancouver, ISO, and other styles
41

Dolgopolov, I. S., L. Yu Grivtsova, O. K. Ustinova, and M. Yu Rykov. "Primary immunodeficiency in a patient with Kabuki syndrome." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 67, no. 6 (2023): 104–12. http://dx.doi.org/10.21508/1027-4065-2022-67-6-104-112.

Full text
Abstract:
Kabuki syndrome is a well-known disease characterized by postnatal growth failure, dysmorphic facial features, skeletal abnormalities, and mental retardation associated with one of the pathogenic mutations in the KMT2D or KDM6A genes. At least 50% of individuals with Kabuki syndrome tend to develop recurrent infections and immune abnormalities, primarily hypogammaglobulinemia. The article describes the clinical course of resistant infectious syndrome in an 18-month-old child without typical dysmorphic and dermatoglyphic manifestations characteristic of Kabuki syndrome. A long history of resist
APA, Harvard, Vancouver, ISO, and other styles
42

Nurul, Nasyifa, Billy Muchamad Ramdani, and Indra Gunawan Affandi. "Acute Hemiballismus Due to Vascular or Diabetic Striatopathy: A Rare Case Report from KHZ Musthafa General Hospital, Tasikmalaya." Magna Neurologica 3, no. 2 (2025): 99–103. https://doi.org/10.20961/magnaneurologica.v3i2.2276.

Full text
Abstract:
Background: Hemiballismus is a hyperkinetic movement disorder characterized by sudden, involuntary, high-amplitude ballistic movements of the arm and leg on one side of the body, often due to contralateral central nervous system dysfunction. The most common causes are ischemic stroke and hyperosmolar hyperglycemic syndrome. Stroke-related movement disorders are rare, with an incidence of 0.4%–0.54%, while the prevalence of hyperglycemia-induced, known as diabetic striatopathy (DS), affects approximately 1 in 100,000 individuals, predominantly older women. Case: A 63-year-old male presented wit
APA, Harvard, Vancouver, ISO, and other styles
43

Vijiaratnam, Nirosen, Kailash P. Bhatia, Anthony E. Lang, Wendy H. Raskind, and Alberto J. Espay. "ADCY5–Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder." Movement Disorders Clinical Practice 6, no. 7 (2019): 512–20. https://doi.org/10.1002/mdc3.12816.

Full text
Abstract:
Background:The phenotypic spectrum of adenylyl cyclase 5 (ADCY5)-related disease has expanded considerably since the first description of the disorder in 1978 as familial essential chorea in a multiplex family. Objective:To examine recent advances in the understanding of ADCY5-related dyskinesia and outline a diagnostic approach to enhance clinical detection. Methods:A pragmatic review of the ADCY5 literature was undertaken to examine unique genetic and pathophysiological features as well as distinguishing clinical features. Results:With over 70 cases reported to date, the phenotype is recogni
APA, Harvard, Vancouver, ISO, and other styles
44

Jha, Shreyashi, Netravathi M, Vikram Venkappayya Holla, Nitish Kamble, Anita Mahadevan, and Pramod Kumar Pal. "Movement disorders in autoimmune encephalitis: Clinical spectrum, prognosis, and outcomes from an Indian cohort." Annals of Movement Disorders 7, no. 3 (2024): 189–95. https://doi.org/10.4103/aomd.aomd_44_24.

Full text
Abstract:
Abstract BACKGROUND: Antibody-mediated autoimmune encephalitis (AE) encompasses inflammatory central nervous system disorders linked etiologically with neuronal autoantibodies. Movement disorders (MDs) are common and diverse in AE, and their early identification can expedite effective management. Current literature on MDs in AE is limited to a few case reports and series, synthesized into multiple systematic reviews. Furthermore, there is a lack of literature on MDs in seronegative AE and their prognostic factors. We aimed to characterize the age-specific phenomenology, therapeutic responses,
APA, Harvard, Vancouver, ISO, and other styles
45

Gorbunov, Alexey, Evgenii Tugolukov, Dmitry Parshin, Polina Polyanskaya, Alexey Loktev, and Marina Vlasova. "TIC HYPERKINESIS IN FIRST-YEAR STUDENTS AGED 17-19." Archiv Euromedica 14, no. 6 (2024). https://doi.org/10.35630/2024/14/6.605.

Full text
Abstract:
The clinical picture of tics and hyperkinesis manifested by involuntary movements and/or sounds is relevant primarily due to its impact on the quality of life and social adaptation of people, especially during their studies and early careers. To analyze tics in young people, we examined 80 people (37 women (46.3%) and 43 men (53.7%)), first-year students of a medical university aged 17 to 19 years without complaints and clear anamnestic indications of tic hyperkinesis during the routine educational process. Along with the standard clinical and neurological examination, we assessed hyperkinesis
APA, Harvard, Vancouver, ISO, and other styles
46

Erbguth, Frank, and Rüdiger Lange. "Sensory trick effect in craniofacial dystonia as one of the possible impacts of wearing face masks during the COVID-19 pandemic." Neurological Research and Practice 3, no. 1 (2021). http://dx.doi.org/10.1186/s42466-021-00123-2.

Full text
Abstract:
Abstract Background The report of a patient with blepharospasm during the COVID-19 pandemic suggested a potential ameliorating effect of wearing a face mask. Objective We prospectively evaluated a possible symptom change through wearing a face mask in all consecutive patients with craniofacial hyperkinesias in our botulinum toxin outpatient treatment cohort. Methods Patients with craniofacial hyperkinesia were asked to rate changes of symptoms between − 2 (markedly worsened), − 1 (slightly worsened), 0 (no change), + 1 (slightly improved) and + 2 (markedly improved). Results Of 101 patients (1
APA, Harvard, Vancouver, ISO, and other styles
47

Makhdoom, N., A. S. Chaudry, and Zhen Yu Wong. "373 The Use of Botulinum Toxin to Improve Cosmesis in Patients with Facial Asymmetry Following Facial palsy/synkinesis." British Journal of Surgery 111, Supplement_6 (2024). http://dx.doi.org/10.1093/bjs/znae163.509.

Full text
Abstract:
Abstract Aim Facial Palsy (FP) is a common, debilitating condition with a broad range of aetiologies. It causes unilateral paralysis, functional impairments, and asymmetry resulting in overall reduced facial aesthetics. Secondary complications like hyperkinesis or synkinesis can result in a reduced quality of life, including social isolation and deteriorating mental health. Treatments, including botulinum toxin (BTX) injections, aim to correct this asymmetry. This review assesses BTX's efficacy, safety, and cost-effectiveness for enhancing facial symmetry in FP. Method PubMed was used to find
APA, Harvard, Vancouver, ISO, and other styles
48

Dressler, D., and P. W. Sch�nle. "Botulinum toxin to suppress hyperkinesias after hypoglossal-facial nerve anastomosis." European Archives of Oto-Rhino-Laryngology 247, no. 6 (1990). http://dx.doi.org/10.1007/bf00179017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Khandelwal, Dinesh, Neha Pemassini, Ashish Pemawat, and Vaibhav Mathur. "ADCY5-related dyskinesias: An amalgamation of various hyperkinetic movement disorders." Annals of Movement Disorders, March 21, 2024. http://dx.doi.org/10.4103/aomd.aomd_35_23.

Full text
Abstract:
Abstract Adenylyl cyclase 5 (ADCY5)-related dyskinesia is a rare disorder characterized by early-onset paroxysmal choreoathetosis, dystonia, myoclonus, or a combination thereof, primarily involving the limbs, face, and neck. Other core clinical features include nocturnal ballistic bouts and facial dyskinesias, often followed by remission during adolescence, as well as axial hypotonia. Any mixed movement disorder accompanied by the aforementioned core features should prompt genetic testing for ADCY5 mutation. We report the case of a 31-year man from North India with a childhood-onset history of
APA, Harvard, Vancouver, ISO, and other styles
50

Shimojima Yamamoto, Keiko, Tomoe Yanagishita, Hisako Yamamoto, et al. "Recurrent de novo pathogenic variant of WASF1 in a Japanese patient with neurodevelopmental disorder with absent language and variable seizures." Human Genome Variation 8, no. 1 (2021). http://dx.doi.org/10.1038/s41439-021-00176-4.

Full text
Abstract:
AbstractA recurrent de novo pathogenic variant of WASF1, NM_003931:c.1516C>T [p.Arg506*], was identified in a 6-year-old female Japanese patient with severe developmental delay, hypotonia, hyperkinetic behavior, and distinctive facial features. The initial report of five adult patients with WASF1 variants was the only previous report regarding variants of this gene; this is the second such report, reaffirming that rare but recurrent truncating variants of WASF1 are associated with severe neurodevelopmental disorders.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!